Lindsey Makovicka
Family · Aurora, NENPI 1881173797
Payments from drug & device makers
Across 102 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$562
- Gilead$186
- Astellas Pharma US Inc$111
- Exact Sciences$106
- Novo Nordisk$102
- AstraZeneca$54
- plus $546 from 19 others
What the payments were for
- Food & beverage$1,668100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $562 |
| Gilead | 10 | $186 |
| Astellas Pharma US Inc | 7 | $111 |
| Exact Sciences | 7 | $106 |
| Novo Nordisk | 7 | $102 |
| AstraZeneca | 4 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Pfizer | 3 | $48 |
| Merck | 3 | $46 |
| Novartis | 3 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $32 |
| Dexcom, Inc. | 2 | $32 |
| Bayer | 2 | $27 |
| GSK | 2 | $25 |
| Medtronic | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $15 |
| Abbott | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,668 in reported general payments places this provider in the 80th percentile of 809 family providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 18 | $24,807 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,175 |
| RybelsusSemaglutide | 16 | $19,974 |
| EliquisApixaban | 23 | $18,424 |
| MounjaroTirzepatide | 16 | $17,480 |
| XareltoRivaroxaban | 16 | $13,607 |
| JardianceEmpagliflozin | 18 | $12,600 |
| OzempicSemaglutide | 12 | $9,691 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 26 | $7,702 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,488 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 37 | $2,905 |
| Atorvastatin Calcium | 224 | $2,482 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 12 | $2,465 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,219 |
| Pravastatin Sodium | 104 | $2,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $102 | $29,66528 claims |
| PfizerEliquis, Abrysvo | $48 | $26,12649 claims |
| GSKTrelegy Ellipta, Shingrix | $25 | $25,64048 claims |
| AstraZenecaFarxiga | $54 | $24,80718 claims |
| Lilly USA, LLCMounjaro | $44 | $17,48016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Nebraska.
Other family in Aurora
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
- Mary MetzLincoln$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.